Search

Search Constraints

You searched for: Author/Creator Pfeffer, Marc A.

Search Results

1. 2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials. Issue 9 (27th February 2018)

2. Analysing recurrent hospitalizations in heart failure: a review of statistical methodology, with application to CHARM‐Preserved. (18th December 2013)

3. Angiotensin-Neprilysin Inhibition and Renal Outcomes in Heart Failure With Preserved Ejection Fraction. Issue 13 (29th September 2020)

4. Angiotensin–neprilysin inhibition and renal outcomes across the spectrum of ejection fraction in heart failure. (18th January 2022)

6. Association of diabetes and kidney function according to age and systolic function with the incidence of sudden cardiac death and non‐sudden cardiac death in myocardial infarction survivors with heart failure. (2nd September 2019)

7. Association of Hyper-Polypharmacy With Clinical Outcomes in Heart Failure With Preserved Ejection Fraction. (November 2021)

8. Baseline characteristics of patients in the Reduction of Events with Darbepoetin alfa in Heart Failure trial (RED‐HF). (March 2013)

9. Baseline Characteristics of Patients With Heart Failure and Preserved Ejection Fraction in the PARAGON-HF Trial. (July 2018)

10. Baseline Distribution of Participants With Depression and Impaired Quality of Life in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist Trial. (March 2015)